Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19656262 | 0.88 | ELANE (0.49) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL19656230 | 0.86 | ELANE (0.47) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL19656228 | 0.86 | ELANE (0.47) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL21796103 | 0.83 | ELANE (0.46) | ELANEMEN1KMT2ACTSK | |
| Benzene SCHEMBL19639966 | 0.82 | ELANE (0.46) | ELANEMEN1KMT2A | |
| SCHEMBL19640000 | 0.82 | ELANE (0.56) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL19656257 | 0.81 | ELANE (0.47) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL19684694 | 0.80 | ELANE (0.56) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL19639985 | 0.80 | ELANE (0.56) | ELANEMEN1KMT2ACTSK | |
| SCHEMBL19656269 | 0.80 | ELANE (0.47) | ELANEMEN1KMT2ACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885MEN1 4540/4885KMT2A 4327/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | ELANE 2/4885MEN1 4112/4885KMT2A 4207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.